| Literature DB >> 35610346 |
Alice Nevone1,2, Maria Girelli1,2, Silvia Mangiacavalli3, Bruno Paiva4, Paolo Milani1,2, Pasquale Cascino1,2, Maggie Piscitelli1,2, Valentina Speranzini5, Claudio Salvatore Cartia3, Pietro Benvenuti2,3, Ibai Goicoechea4, Francesca Fazio6, Marco Basset1,2, Andrea Foli1,2, Martina Nanci1,2, Giulia Mazzini1,2, Serena Caminito1,2, Melania Antonietta Sesta1,2, Simona Casarini1,2, Paola Rognoni1,2, Francesca Lavatelli1,2, Maria Teresa Petrucci6, Pier Paolo Olimpieri7, Stefano Ricagno5,8, Luca Arcaini1,3, Giampaolo Merlini1,2, Giovanni Palladini9,10, Mario Nuvolone11,12.
Abstract
Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC). The pathogenicity of LCs is encrypted in their sequence, yet molecular determinants of amyloidogenesis are poorly understood. Higher rates of N-glycosylation among clonal κ LCs from patients with AL amyloidosis compared to other monoclonal gammopathies indicate that this post-translational modification is associated with a higher risk of developing AL amyloidosis. Here, we exploited LC sequence information from previously published amyloidogenic and control clonal LCs and from a series of 220 patients with AL amyloidosis or multiple myeloma followed at our Institutions to define sequence and spatial features of N-glycosylation, combining bioinformatics, biochemical, proteomics, structural and genetic analyses. We found peculiar sequence and spatial pattern of N-glycosylation in amyloidogenic κ LCs, with most of the N-glycosylation sites laying in the framework region 3, particularly within the E strand, and consisting mainly of the NFT sequon, setting them apart with respect to non-amyloidogenic clonal LCs. Our data further support a potential role of N-glycosylation in determining the pathogenic behavior of a subset of amyloidogenic LCs and may help refine current N-glycosylation-based prognostic assessments for patients with monoclonal gammopathies.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35610346 DOI: 10.1038/s41375-022-01599-w
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 12.883